Convert Ultima ULTIMA to VitaStem VITASTEM

Ultima (ULTIMA) is the infrastructure token of the Ultima ecosystem. This cryptocurrency is based on an easily scalable Smart Blockchain that runs on the DPoS (Delegated Proof of Stake) consensus algorithm. The Smart Blockchain network is known by its unique throughput — it can conduct up to 2000 transactions per second. Moreover, the network creates a new block every three seconds and has low transaction costs. All these factors make ULTIMA a perfect digital currency for making daily transactions around the globe. Right now, the Ultima ecosystem includes a number of innovative blockchain products, such as DeFi-U, a technology that allows users to receive staking rewards in Ultima tokens, and a marketplace. The Ultima technical team, which has over twenty years of experience in the blockchain industry, is actively working on launching a physical crypto debit card, crypto exchange, and travel and crowdfunding platforms. ULTIMA was first launched in March 2023. Currently, the project community has reached more than 2.8 million users from 120 countries. Mission: To become the world's most widespread digital currency and an ecosystem accessible to everyone in the crypto space.

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.